Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 29, 2025: USD 14.70 B

Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) is USD 14.70 B for the Trailing 12 Months (TTM) ending March 29, 2025, a 0.82% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.
  • Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 14.58 B, a 1.90% change year over year.
  • Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending April 02, 2023 was USD 14.31 B, a 14.19% change year over year.
  • Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending April 03, 2022 was USD 12.53 B, a -0.44% change year over year.
  • Pfizer Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending April 04, 2021 was USD 12.59 B, a -9.35% change year over year.
Key Data
Date Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses Revenue Revenue